More than 30 million Americans are using GLP-1 medications such as Ozempic and Mounjaro, which are primarily prescribed for managing type 2 diabetes but have also gained popularity for weight loss. These drugs, which work by slowing digestion and reducing appetite, can cost hundreds of dollars per month even with health insurance. However, experts are warning that these costs could potentially double if employers stop covering the medications, which many have done in recent months. According to a May survey by the Business Group, an employer organization, two-thirds of U.S. companies currently cover GLP-1 medications for weight loss. However, 10 percent of these companies are planning to eliminate this coverage by next year. This shift is expected to contribute to a record increase in the costs of employer-sponsored health insurance, as noted in a separate survey by the global insurance firm Marsh. Some companies have already taken action, including PepsiCo, which has removed coverage for GLP-1 drugs used for weight loss. The company stated in a letter to employees that these medications have become one of the fastest-growing costs in their health plans and that removing coverage helps maintain an affordable and sustainable healthcare program. Cigna, a major healthcare provider, and Starbucks, the coffee chain, have also stopped covering GLP-1 medications for weight loss. Cigna explained that the decision was made due to the increasing availability of alternative weight management options, while still offering support through other health programs. The Independent has reached out to both Cigna and Starbucks for further comment. Meanwhile, some companies have highlighted the benefits of GLP-1 drugs. For example, Bank of America CEO Brian Moynihan told CNBC that the company spends over $250 million annually on these medications, a significant increase from just a few years ago. He emphasized the positive impact on employee health, including reduced sick days. Recent studies suggest that GLP-1 medications may not only improve health but also extend life expectancy, although more research is needed to confirm these findings. As the use of these drugs continues to grow, the balance between their benefits and the rising costs they pose for employers and insurers remains a key issue in the healthcare landscape.